Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial

被引：31
|
作者：
Claggett, Brian [1 ]
Lachin, John M. [2 ]
Hantel, Stefan [3 ]
Fitchett, David [4 ,5 ]
Inzucchi, Silvio E. [6 ]
Woerle, Hans J. [7 ]
George, Jyothis T. [7 ]
Zinman, Bernard [5 ,8 ]
机构：
[1] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[2] George Washington Univ, Biostat Ctr, Rockville, MD USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[4] St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
[7] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[8] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CIRCULATION | 2018年 / 138卷 / 15期
关键词：
cardiovascular diseases; diabetes mellitus; empagliflozin;
D O I：
10.1161/CIRCULATIONAHA.118.033810
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1599 / 1601
页数：3
相关论文
共 50 条
  • [41] Impact of Duration of Diabetes Mellitus on Long-Term Outcome in Type 2 Diabetic Patients with Primary Percutaneous Coronary Intervention after the First Myocardial Infarction
    Yaliqin, Nazila
    Aimaier, Salamaiti
    Adi, Dilare
    Ma, Yi-Tong
    Yu, Zi-Xiang
    CARDIOLOGY, 2024, 149 (04) : 297 - 313
  • [42] Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis
    Zhang, Xin-Lin
    Zhu, Qing-Qing
    Chen, Yu-Han
    Li, Xue-Ling
    Chen, Fu
    Huang, Jian-An
    Xu, Biao
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (02):
  • [43] The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
    Mellbin, Linda G.
    Malmberg, Klas
    Norhammar, Anna
    Wedel, Hans
    Ryden, Lars
    EUROPEAN HEART JOURNAL, 2008, 29 (02) : 166 - 176
  • [44] Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT)
    Tanaka, Atsushi
    Imai, Takumi
    Toyoda, Shigeru
    Sugimoto, Kazuhiro
    Yoshida, Ruka
    Furuta, Machi
    Node, Koichi
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01)
  • [45] High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus
    Makino, Aritaka
    Nakamura, Takamitsu
    Hirano, Mitsumasa
    Kitta, Yoshinobu
    Sano, Keita
    Kobayashi, Tsuyoshi
    Fujioka, Daisuke
    Saito, Yukio
    Watanabe, Kazuhiro
    Watanabe, Yosuke
    Kawabata, Ken-ichi
    Obata, Jun-ei
    Kugiyama, Kiyotaka
    ATHEROSCLEROSIS, 2010, 213 (02) : 573 - 578
  • [46] Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial
    Homa Taheri
    Hossein Chiti
    Tara Reshadmanesh
    Sepehr Gohari
    Ahmad Jalilvand
    Shahram Arsang-Jang
    Faramarz Ismail-Beigi
    Samin Ghanbari
    Mohsen Dadashi
    Atieh Asgari
    Mahsa Mahjani
    Amir Karbalaee‑Hasani
    Hassan Ahangar
    Journal of Diabetes & Metabolic Disorders, 2023, 22 : 1723 - 1730
  • [47] Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial
    Taheri, Homa
    Chiti, Hossein
    Reshadmanesh, Tara
    Gohari, Sepehr
    Jalilvand, Ahmad
    Arsang-Jang, Shahram
    Ismail-Beigi, Faramarz
    Ghanbari, Samin
    Dadashi, Mohsen
    Asgari, Atieh
    Mahjani, Mahsa
    Karbalaee-Hasani, Amir
    Ahangar, Hassan
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2023, 22 (02) : 1723 - 1730
  • [48] Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial
    Tanaka, Atsushi
    Shimabukuro, Michio
    Machii, Noritaka
    Teragawa, Hiroki
    Okada, Yosuke
    Shima, Kosuke R.
    Takamura, Toshinari
    Taguchi, Isao
    Hisauchi, Itaru
    Toyoda, Shigeru
    Matsuzawa, Yasushi
    Tomiyama, Hirofumi
    Yamaoka-Tojo, Minako
    Ueda, Shinichiro
    Higashi, Yukihito
    Node, Koichi
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (06) : 1551 - 1563
  • [49] Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial
    Briggs, Andrew H.
    Bhatt, Deepak L.
    Scirica, Benjamin M.
    Raz, Itamar
    Johnston, Karissa M.
    Szabo, Shelagh M.
    Bergenheim, Klas
    Mukherjee, Jayanti
    Hirshberg, Boaz
    Mosenzon, Ofri
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 130 : 24 - 33
  • [50] Prognostic value of coronary flow reserve assessed by transthoracic Doppler echocardiography on long-term outcome in asymptomatic patients with type 2 diabetes without overt coronary artery disease
    Takayuki Kawata
    Masao Daimon
    Rei Hasegawa
    Tomohiko Toyoda
    Tai Sekine
    Toshiharu Himi
    Daigaku Uchida
    Sakiko Miyazaki
    Kuniaki Hirose
    Ryoko Ichikawa
    Masaki Maruyama
    Hiromasa Suzuki
    Hiroyuki Daida
    Cardiovascular Diabetology, 12
12345